Intellia cuts 27% of staff

Gene editing stocks drop as Intellia announces layoffs
Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to lay off 27% of its staff alongside a decision to halt a mid-stage clinical program targeted at a rare genetic disorder.
Intellia cuts 27% of staff, in the latest wave of gene-editing layoffs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Ready for JPM?
CRISPR biotech Intellia cuts staff as it eyes 2027 launch
In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR therapy – saying the results suggested it could offer a "functional cure" for HAE by switching off a gene involved in the potentially life-threatening inflammatory attacks that characterise the disease.
Intellia to stop work on rare disease therapy, lay off staff
The CRISPR gene editing company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.
Intellia Therapeutics to Lay Off 27% of Workers in Reorganization
Intellia Therapeutics will cut about 27% of its workforce, or roughly 142 jobs, this year in a cost-savings push intended to support its operations into the first half of 2027, when it expects to launch its first commercial product in the U.S.
Intellia Therapeutics announces net workforce reduction of 27% in 2025
Intellia Therapeutics (NTLA) announced a strategic reorganization focused on key value drivers. The pipeline prioritization is intended to
Intellia cuts 27% of workforce as it eyes commercial launch
Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development biotech to a commercial-ready company by the end of 2026.
Intellia to cut 27% of workforce, discontinue NTLA-3001
Intellia Therapeutics (NASDAQ:NTLA) said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the company cutting around 27% of its workforce.
FierceBiotech1d
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
Evercore ISI lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $60 and keeps an Outperform rating on the shares after ...
precisionmedicineonline15h
Intellia Cuts AATD Gene Insertion Program, 27 Percent of Workforce in Strategic Reorganization
These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...
Strategic Shifts and Promising Pipelines Position Intellia Therapeutics for Growth
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) yesterday and set a price target of ...
bovnews3d
How Does Intellia Therapeutics Inc (NTLA) Stack Up Against Its Industry Peers?
Goldman has recently reduced Intellia Therapeutics Inc (NTLA) stock to Neutral rating, as announced on February 23, 2024, according to Finviz. Earlier, on February 15, 2024, Wolfe Research had ...